Results 181 to 190 of about 69,283 (286)

Targeted Alkaline Phosphatase Therapy Enhances Alveolar Bone Healing in X‐Linked Hypophosphatemia in Mice

Journal of Periodontal Research, EarlyView.
Effects of exogenous tissue‐nonspecific alkaline phosphatase (TNAP) were analyzed in the Hyp mouse model of X‐linked hypophosphatemia (XLH). Maxillary first molars were extracted from wild‐type (WT) and Hyp mice at 6 weeks, and collagen gel ± TNAP was placed in sockets. In one group of Hyp mice, submucosal injections of TNAP or saline were delivered at
Aonjittra Phanrungsuwan, Bella Donnelly, José Luis Millán, Brian L. Foster   +3 more
wiley   +1 more source

Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue. [PDF]

Int J Endocrinol, 2020
Antinozzi C, Sgrò P, Di Luigi L.
europepmc   +1 more source

Krisanaklan Reduces Intestinal Anion and Fluid Secretion Through Inhibition of Na+/K+‐ATPase and K+ Channel Activity

Annals of the New York Academy of Sciences, EarlyView.
Krisanaklan reduces CFTR‐dependent intestinal chloride and fluid secretion by inhibiting the Na+,K+‐ATPase and K+ channels in epithelial cells. Consequently, this natural, plant‐derived product may limit secretory diarrhea caused by a diverse array of microbial pathogens. However, by dissipating the transmembrane Na+ gradient, Krisanaklan also inhibits
Tessa A. Groeneweg, Erdene Baigal, Anny Leung, Gert‐Jan Kremers, Marcel J. C. Bijvelds   +4 more
wiley   +1 more source

Effect of phosphodiesterase type 5 inhibitors on surgical outcome of ventricular septal defect and pulmonary hypertension patients. [PDF]

Egypt Heart J
Shams KA, Ellahony DM, Halima AF, Elzayat RS.   +3 more
europepmc   +1 more source

Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience

Experimental Physiology, EarlyView.
Abstract The phosphodiesterase‐5 inhibitor sildenafil suppresses ventricular arrhythmias in a sheep model of drug‐induced long QT. In that study, ventricular arrhythmias were abolished by reducing premature ventricular complexes (PVCs) and delaying PVC onset, thus preventing ‘R‐on‐T’ ventricular tachycardia.
David C. Hutchings, Christopher P. Denton, Luigi Venetucci, Andrew W. Trafford   +3 more
wiley   +1 more source

Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy? [PDF]

J Urol
Flores JM, Vertosick E, Jenkins LC, Cooper J, Benfante N, Sjoberg D, Vickers AJ, Eastham JA, Laudone VP, Scardino PT, Nelson CJ, Mulhall JP.   +11 more
europepmc   +1 more source

Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology. [PDF]

Clin Immunol, 2020
Dal Moro F, Livi U.
europepmc   +1 more source

Phosphodiesterase type 5 inhibitors related hearing impairment: a real world study based on the FDA adverse event reporting system. [PDF]

Sci Rep
Zhang X, Xia L, Yang Q, Tang P.
europepmc   +1 more source

Sodium thiosulfate treatment rescues hyperglycaemia‐induced pronephros damage in zebrafish by upregulating nitric oxide signalling

The Journal of Physiology, EarlyView.
Abstract figure legend Sodium thiosulfate (STS) rescues the pronephros phenotype of pdx1 morphants through compensatory upregulation of nitric oxide (NO) metabolism. Zebrafish larvae injected with a control morpholino show the typical pronephros structure at 48 h post‐fertilization (hpf) with and without STS treatment.
Hannes Ott, Katrin Bennewitz, Xin Zhang, Mariia Prianichnikova, Carsten Sticht, Gernot Poschet, Jens Kroll   +6 more
wiley   +1 more source

Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation. [PDF]

J Am Heart Assoc, 2020
Xanthopoulos A, Tryposkiadis K, Triposkiadis F, Fukamachi K, Soltesz EG, Young JB, Wolski K, Blackstone EH, Starling RC.   +8 more
europepmc   +1 more source